Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 26;15(1):143.
doi: 10.1038/s41408-025-01353-2.

Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis

Akhil Rajendra  1 , Elliot Smith  2 , Maria Agustina Perusini  1 , Kenny Tang  3 , Eshetu G Atenafu  4 , Aniket Bankar  1 , Steven Chan  1 , Marta B Davidson  1 , Vikas Gupta  1 , Dawn Maze  1 , Mark D Minden  1   5 , Guillaume Richard-Carpentier  1 , Aaron D Schimmer  1 , Andre C Schuh  1 , Karen Yee  1 , Hassan Sibai  6
Affiliations

Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis

Akhil Rajendra et al. Blood Cancer J. .

Abstract

PubMed Disclaimer

Conflict of interest statement

Competing interests: This study has not been funded by any pharmaceutical companies. There were no direct COI specifically related to this research project. ADS has received research funding from Takeda Pharmaceuticals, BMS and Medivir AB, and consulting fees/honorarium from Takeda, Novartis, Jazz, and Otsuka Pharmaceuticals. ADS is named on a patent application for the use of DNT cells to treat AML. ADS is a member of the Medical and Scientific Advisory Board of the Leukemia and Lymphoma Society of Canada. The remaining authors declare no competing interests. Ethics approval statement: The study was approved by research ethics board (REB) and waiver of consent was granted. Patient consent statement: Waiver of consent was granted by the REB.

Figures

Fig. 1
Fig. 1. Survival outcomes in patients treated with gilteritinib-based therapies.
A Event-free survival comparison between patients receiving gilteritinib monotherapy and gilteritinib combination therapies. B Overall survival comparison between patients receiving gilteritinib monotherapy and gilteritinib combination therapies.
See this image and copyright information in PMC

References

    1. Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381:1728–40. - PubMed
    1. Singh Mali R, Zhang Q, DeFilippis RA, Cavazos A, Kuruvilla VM, Raman J, et al. Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models. Haematologica. 2021;106:1034–46. - PMC - PubMed
    1. Brinton LT, Zhang P, Williams K, Canfield D, Orwick S, Sher S, et al. Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia. J Hematol Oncol. 2020;13:139. - PMC - PubMed
    1. Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, et al. Venetoclax plus gilteritinib for FLT3-mutated relapsed/refractory acute myeloid leukemia. J Clin Oncol. 2022;40:4048–59. - PMC - PubMed
    1. Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, et al. Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML. J Clin Oncol. 2024;42:1499–508. - PMC - PubMed

LinkOut - more resources